Related references
Note: Only part of the references are listed.Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
Jee Wan Wee et al.
BLOOD RESEARCH (2014)
Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab
Paraskevi A. Vlachou et al.
JOURNAL OF HEPATOLOGY (2013)
Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab
Gwo Yaw Ho et al.
MEDICAL JOURNAL OF AUSTRALIA (2013)
Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)
Ajay Chavan et al.
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE (2013)
Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia
Brian T. Brinkerhoff et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2012)
Iron Deficiency Anemia Related to Hereditary Hemorrhagic Telangiectasia: Response to Treatment With Bevacizumab
Jessica M. Fleagle et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2012)
Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
Sophie Dupuis-Girod et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Low Dose of Bevacizumab Is Safe and Effective in Preventing Bleeding Episodes in Hereditary Hemorrhagic Telangiectasia
Georgia Lazaraki et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia
Philip Fodstad et al.
ANNALS OF HEMATOLOGY (2011)
Efficacy of Intranasal Bevacizumab (Avastin) Treatment in Patients with Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis
Tom T. Karnezis et al.
LARYNGOSCOPE (2011)
Long-Term Therapy with Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Brian T. Brinkerhoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia
Suppressa Patrizia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A Case Report of a Patient with Hereditary Hemorrhagic Telangiectasia Treated Successively with Thalidomide and Bevacizumab
Ahmad Amanzada et al.
CASE REPORTS IN ONCOLOGY (2010)
Bevacizumab in Hereditary Hemorrhagic Telangiectasia
Prithviraj Bose et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Andrew Mitchell et al.
LIVER TRANSPLANTATION (2008)
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab
Dimitri Flieger et al.
ANNALS OF HEMATOLOGY (2006)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Share Paper
